alphav Vitronectin receptors in vascular-mediated disorders

Area of Science:

• Integrin biology and pharmacology
• Vascular medicine
• Drug discovery

Background:

• Integrin antagonists are clinically evaluated for disease modulation.
• Integrins play crucial roles in various physiological and pathological processes.
• Vascular disorders present significant therapeutic challenges.

Purpose of the Study:

• To review the therapeutic potential of integrin antagonists.
• To focus on the role of alphav integrins (alphavbeta3 and alphavbeta5) in vascular diseases.
• To discuss applications in restenosis and angiogenesis-mediated disorders.

Main Methods:

• Literature review of clinical evaluations of integrin antagonists.
• Analysis of studies focusing on alphav integrin function.
• Synthesis of data on restenosis and angiogenesis.

Main Results:

• Diverse classes of integrin antagonists (antibodies, peptides, peptidomimetics, non-peptides) show therapeutic promise.
• Alphav integrins (alphavbeta3 and alphavbeta5) are implicated in vascular pathologies.
• Modulation of these integrins offers potential treatment strategies.

Conclusions:

• Integrin antagonists represent a viable therapeutic strategy for vascular disorders.
• Targeting alphav integrins is a key approach for managing restenosis and angiogenesis-related conditions.
• Further research into integrin-targeted therapies is warranted.